YM-155 Hydrochloride: Selective Survivin Inhibitor for Cancer Models

Executive Summary: YM-155 hydrochloride is a nanomolar-range small-molecule inhibitor that selectively targets survivin, an inhibitor of apoptosis protein critical for tumor survival (product information). It exhibits an IC50 value of 0.54 nM against survivin with negligible effects on other IAP or BCL-2 proteins. The compound induces tumor regression in xenograft models of non-small cell lung cancer (NSCLC), melanoma, and triple-negative breast cancer (TNBC) (reference study). YM-155 hydrochloride is highly soluble in DMSO, ethanol, and water under defined conditions, and is intended for research use only. APExBIO provides the A3947 kit for laboratory workflows.

Biological Rationale

Survivin (BIRC5) is the smallest member of the inhibitor of apoptosis (IAP) protein family and is frequently overexpressed in malignancies. Its upregulation confers resistance to cell death and correlates with poor prognosis in multiple cancer types (Schwartz 2022). Targeting survivin is a validated strategy to restore apoptosis sensitivity and suppress tumor growth. YM-155 hydrochloride was designed to disrupt survivin function selectively, minimizing toxicity associated with broad-spectrum apoptosis inhibitors. Selective survivin suppression has shown efficacy in NSCLC, melanoma, bladder, aggressive non-Hodgkin lymphoma, and breast cancer models.

Mechanism of Action of YM-155 hydrochloride

YM-155 hydrochloride binds to the survivin promoter region, inhibiting its transcription and protein expression. This suppression leads to increased apoptotic response in cancer cells. The compound demonstrates minimal activity against other IAPs or BCL-2 family proteins, indicating high selectivity at the molecular level (product information). Unlike pan-apoptosis inhibitors, YM-155 offers precise modulation of apoptotic pathways, reducing off-target effects.

Evidence & Benchmarks

• YM-155 hydrochloride inhibits survivin with an IC50 of 0.54 nM in biochemical assays (product information).
• The compound suppresses proliferation in a broad panel of human cancer cell lines, including NSCLC, melanoma, bladder, aggressive non-Hodgkin lymphoma, and breast cancer lines (Schwartz 2022).
• Significant tumor regression is observed in xenograft models treated with YM-155 hydrochloride, with pronounced effects in non-small cell lung and triple-negative breast cancer models (Schwartz 2022).
• In vivo studies report a reduction in spontaneous metastases and marked extension of survival in metastatic tumor-bearing mice (product information).
• The compound exhibits solubility of ≥19.45 mg/mL in DMSO, ≥4.34 mg/mL in ethanol (with gentle warming and ultrasound), and ≥48.1 mg/mL in water (with ultrasound), facilitating flexible experimental formulation (product information).

This article builds on and extends practical protocols described in Applied Use-Cases of YM-155 Hydrochloride: Survivin Inhibitor Workflows by providing new benchmarks, while contrasting with Redefining Survivin Inhibition: YM-155 Hydrochloride in Translational Oncology by focusing on verifiable in vitro and in vivo efficacy metrics. For advanced methodological guidance, see Workflow Advances for Survivin Inhibitor Research, which this article updates with current solubility and selectivity data.

Applications, Limits & Misconceptions

YM-155 hydrochloride is validated for use in apoptosis inhibitor research, tumor regression studies, and survivin-targeted drug discovery. Its specificity enables mechanistic dissection of survivin’s role in cancer cell death. However, its utility is limited to research settings; clinical translation requires further toxicity and pharmacokinetic evaluation.

Common Pitfalls or Misconceptions

• YM-155 hydrochloride is not effective against cancers lacking survivin overexpression.
• The compound does not broadly inhibit other IAP or BCL-2 proteins—activity is highly survivin-selective.
• Long-term solution storage is not recommended; degradation can affect reproducibility (product information).
• YM-155 hydrochloride is not approved for diagnostic or therapeutic use in humans.
• Off-target cytotoxicity is minimal but not absent at very high concentrations; titration is advised.

Workflow Integration & Parameters

• Compound reconstitution: Dissolve at ≥19.45 mg/mL in DMSO, ≥4.34 mg/mL in ethanol (gentle warming/ultrasonication), or ≥48.1 mg/mL in water (ultrasonic treatment).
• Storage conditions: Store powder at -20°C; avoid repeated freeze-thaw cycles. Solutions should be freshly prepared and not kept long-term.
• Treatment concentration: Typical in vitro studies use nanomolar to low micromolar range, with initial screens at 0.1–10 nM for survivin inhibition.
• Xenograft dosing: Refer to published protocols for dosing schedules in NSCLC and TNBC models; adjust for mouse strain and tumor load (Schwartz 2022).
• Assay compatibility: Suitable for cell viability, apoptosis, and proliferation assays in standard tissue culture models.

Conclusion & Outlook

YM-155 hydrochloride, as provided by APExBIO, offers a rigorously validated tool for precise survivin inhibition in cancer research. Its nanomolar potency and high selectivity are confirmed in multiple preclinical models (Schwartz 2022). Future work should focus on optimizing delivery and evaluating resistance mechanisms in advanced disease models. The compound remains a cornerstone for apoptosis inhibitor research, with emerging evidence supporting its continued use in both in vitro and translational settings.